The 67th Annual Meeting of the American Society of Hematology (ASH) was held grandly in Orlando from December 6 to 9, 2025, bringing together the latest research and clinical advances…

Despite the remarkable progress achieved with single-target CAR-T therapy in the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL), a proportion of patients still experience suboptimal responses or relapse after treatment. At the 67th Annual Meeting of the American Society of Hematology (ASH), a study led by Professor Wang Liang from Beijing Tongren Hospital, Capital Medical University, was selected for an oral presentation, reporting impressive results from a phase II clinical trial of dual-target CD19/CD22 CAR-T cell therapy in R/R LBCL. The findings attracted wide attention. Hematology Frontier invited Professor Wang Liang for an in-depth discussion of the innovative aspects of this study, offering valuable insights for future optimization of R/R LBCL treatment strategies and research directions.

At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Huang He from the First Affiliated Hospital of Zhejiang University School of Medicine presented multiple innovative studies in the field of hematopoietic stem cell transplantation. These studies covered in-depth analyses of HLA evolutionary divergence (HED), post-transplant maintenance with epigenetic regulatory agents, and other cutting-edge topics, highlighting an integrated translational medicine strategy aimed at addressing key clinical challenges, comprehensively improving transplant outcomes, and enhancing long-term patient survival and quality of life. During the meeting, Hematology Frontier invited Professor Zhao Yanmin from the First Affiliated Hospital of Zhejiang University School of Medicine to systematically interpret the team’s core research achievements, elucidate their clinical value, and discuss future development directions, providing valuable insights for both academic research and clinical practice.